CAS: 1660117-38-3; (S)-2,4-Dimethyl-6-(1-(1-Phenylethyl)-6-(Tetrahydro-2H-Pyran-4-yl)-1H-Imidazo[4,5-C]Pyridin-2-yl)Pyridazin-3(2H)-One
该化合物是一个复杂的有机化合物,其特点是多环结构,包括一个闪烁酮核心和各种替代成分,这可能会助长其化学特性. 蛋白质[4,5-c] 杂类动物的出现表明潜在的生物活动,因为含有此类结构的化合物经常用于药用用途.二甲基组表明,该化合物可能具有特定的消毒特性和电子特性,影响其与生物目标的再活动及相互作用.此外,一个苯乙基乙基化合物和四氢-2H-H-pyran moearmeary moite的存在可能会提高脂性,从而影响化合物的溶性能性和易性.
- 英文名称(S)-2,4-Dimethyl-6-(1-(1-Phenylethyl)-6-(Tetrahydro-2H-Pyran-4-yl)-1H-Imidazo[4,5-C]Pyridin-2-yl)Pyridazin-3(2H)-One
- 中文名称BRD4抑制剂-10
- IUPAC名称(S)-2,4-dimethyl-6-(1-(1-phenylethyl)-6-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl)pyridazin-3(2H)-one
- 其它别名Brd4 Inhibitor-10; Bet Brd4 Inhibitor Compound Ii-25; (S)-2,4-Dimethyl-6-(1-(1-Phenylethyl)-6-(Tetrahydro-2H-Pyran-4-yl)-1H-Imidazo[4,5-C]Pyridin-2-yl)Pyridazin-3(2H)-One; Brd4 Inhibitor 10,Brd-4 Inhibitor-10,Inhibitor,Brd4 Inhibitor-10,Epigenetic Reader Domain,Inhibit,Brd4 Inhibitor10; 3(2H)-Pyridazinone, 2,4-Dimethyl-6-[1-[(1S)-1-Phenylethyl]-6-(Tetrahydro-2H-Pyran-4-yl)-1H-Imidazo[4,5-C]Pyridin-2-Yl]-; Brd4 Inhibitor-10, 10 Mm In Dmso
- CAS编号1660117-38-3
- MFCD编号:MFCD32067915
- 分子式:C25H27N5O2分子量:429.52
- 产品CID: 841666
- 产品分类有机原料 → 有机杂环化合物 → 咪唑并吡啶类
物理性质
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2902600000-乙苯
2905121000-正丙醇
2905130000-正丁醇
2909110000-乙醚 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Tontsch-Grunt U, Traexler PE, Baum A, Musa H, Marzin K, Wang S, Trapani F, Engelhardt H, Solca F. Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic. Br J Cancer. 2022 Aug;127(3):577-586. doi: 10.1038/s41416-022-01815-5. Epub 2022 Apr 20.
2: Schöffski P, Machiels JP, Rottey S, Sadrolhefazi B, Musa H, Marzin K, Awada A. Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours. Eur J Cancer. 2023 Sep;191:112987. doi: 10.1016/j.ejca.2023.112987. Epub 2023 Jul 11.
421:112-120. doi: 10.1016/j.canlet.2018.02.018. Epub 2018 Feb 14. 37(20):2687-2701. doi: 10.1038/s41388-018-0150-2. Epub 2018 Mar 1.
合成参考文献
参考文献:10.1016/j.ejca.2023.112987
摘要:Schöffski P, Machiels JP, Rottey S, Sadrolhefazi B, Musa H, Marzin K, Awada A. Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours. Eur J Cancer. 2023 Sep;191():112987. doi: 10.1016/j.ejca.2023.112987.
📝 需求与反馈
尽可能描述清楚需求与问题信息
